Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-γ agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: Implications for diabetes-impaired skin repair

Molecular Pharmacology

Volumn 74, Issue 4, 2008, Pages 952-963

  Schiefelbein, Dana ^a   Seitz, Oliver ^a   Goren, Itamar ^a   Dißmann, Jan Philipp ^a   Schmidt, Helmut ^a   Bachmann, Malte ^a   Sader, Robert ^a   Geisslinger, Gerd ^a   Pfeilschifter, Josef ^a   Frank, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; CIGLITAZONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; ROSIGLITAZONE; SMALL INTERFERING RNA; TROGLITAZONE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; SKIN INJURY; WOUND HEALING;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CHROMANS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 52949132573     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.049395     Document Type: Article

References (44)

1. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, and Fusenig NE (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771.
2. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, and van de Water L (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375-1379.
3. Chintalgattu V, Harris GS, Akula SM, and Katwa LC (2007) PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res 74:140-150.
4. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
5. Delarue J and Magnan C (2007) Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 10:142-148.
6. Di-Poï N, Tan NS, Michalik L, Wahli W, and Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10:721-733.
7. EmingSAand KriegT (2006) Molecular mechanisms of VEGF-A action during tissue repair. J Investig Dermatol Symp Proc 11:79-86.
8. Faglia E, Favales F, and Morabito A (2001) New ulceration, new major amputation, and survival rates in diabetic subjects hospitalized for foot ulceration from 1990 to 1993: a 6.5 year follow-up. Diabetes Care 24:78-83.
9. Falanga V (2005) Wound healing and its impairment in the diabetic foot. Lancet 366:1736-1743.
10. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, and Werner S (1995) Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270:12607-12613.
11. Frank S, Stallmeyer B, Kämpfer H, Kolb N, and Pfeilschifter J (1999) Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J 13:2002-2014.
12. Frank S, Stallmeyer B, Kämpfer H, Kolb N, and Pfeilschifter J (2000) Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 106:501-509.
13. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, and Tsichlis PN (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3 kinase. Cell 81:727-736.
14. Friedman JM (2003) A war on obesity, not the obese. Science 299:856-858.
15. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
16. Goren I, Kämpfer H, Podda M, Pfeilschifter J, and Frank S (2003) Leptin and wound inflammation in diabetic ob/ob mice: differential regulation of neutrophil and macrophage influx and a potential role for the scab as a sink for inflammatory cells and mediators. Diabetes 52:2821-2832.
17. Goren I, Müller E, Pfeilschifter J, and Frank S (2006) Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice. A potential role of tumor necrosis factor-α. Am J Pathol 168:765-777.
18. Grau R, Punzón C, Fresno M, and Iñiguez MA (2006) Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J 395:81-88.
19. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, and Tannenbaum SR (1982) Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal Biochem 126:131-138.
20. He G, Sung YM, and Fischer SM (2006) Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes. Prostaglandins Leukot Essent Fatty Acids 74:193-197.
21. He G, Thuillier P, and Fischer SM (2004) Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. J Invest Dermatol 123:1110-1119.
22. Henry RR (1997) Thiazolidinediones. Endocrinol Metab Clin North Am 26:553-573.
23. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860-867.
24. Kämpfer H, Pfeilschifter J, and Frank S (2001) Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest 81:361-373.
25. Kanata S, Akagi M, Nishimura S, Hayakawa S, Yoshida K, Sawamura T, Munakata H, and Hamanishi C (2006) Oxidized LDL binding to LOX-1 upregulates VEGF expression in cultured bovine chondrocytes through activation of PPAR-gamma. Biochem Biophys Res Commun 348:1003-10010.
26. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, and Evans RM (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 91:7355-7359.
27. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774.
28. Kömüves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J, and Feingold KR (2000) Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 115:353-360.
29. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270:12953-12956.
30. Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, Moser AH, Michalik L, Desvergne B, Wahli W, et al. (2004) Peroxisome proliferator- activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 123:305-312.
31. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J Cell Biol 154:799-814.
32. Michalik L and Wahli W (2007) Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 1771:991-998.
33. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
34. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, et al. (2002) PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923-932.
35. Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, and Taylor RN (2005) PPARgamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 8:373-379.
36. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, and Bishop-Bailey D (2007) Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27:63-69.
37. Rangwala SM and Lazar MA (2004) Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 25:331-336.
38. Rivier M, Safonova I, Lebrun P, Griffiths CE, Ailhaud G, and Michel S (1998) Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 111:1116-1121.
39. Singer AJ and Clark RAF (1999) Cutaneous wound healing. N Engl J Med 341:738-746.
40. Staels B and Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54:2460-2470.
41. Stallmeyer B, Kämpfer H, Kolb N, Pfeilschifter J, and Frank S (1999) The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Invest Dermatol 113:1090-1098.
42. Stallmeyer B, Pfeilschifter J, and Frank S (2001) Systemically and topically supplemented leptin fails to reconstitute a normal angiogenic response during skin repair in diabetic ob/ob mice. Diabetologia 44:471-479.
43. Tilg H and Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772-783.
44. Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, and DuBois RN (2006) Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A 103:19069-19074.